A detailed history of Nuveen Asset Management, LLC transactions in Oric Pharmaceuticals, Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 167,502 shares of ORIC stock, worth $1.42 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
167,502
Previous 166,193 0.79%
Holding current value
$1.42 Million
Previous $1.17 Million 46.17%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$7.52 - $11.9 $9,843 - $15,577
1,309 Added 0.79%
167,502 $1.72 Million
Q2 2024

Aug 09, 2024

BUY
$6.63 - $12.93 $201,591 - $393,149
30,406 Added 22.39%
166,193 $1.17 Million
Q4 2023

Feb 14, 2024

SELL
$5.41 - $9.43 $179,785 - $313,377
-33,232 Reduced 19.66%
135,787 $1.25 Million
Q2 2023

Aug 14, 2023

BUY
$4.95 - $8.4 $836,644 - $1.42 Million
169,019 New
169,019 $1.31 Million
Q2 2022

Aug 15, 2022

SELL
$2.7 - $7.07 $304,419 - $797,128
-112,748 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$4.54 - $16.1 $7,214 - $25,582
1,589 Added 1.43%
112,748 $753,000
Q4 2021

Feb 14, 2022

SELL
$12.01 - $20.3 $96,776 - $163,577
-8,058 Reduced 6.76%
111,159 $1.31 Million
Q3 2021

Nov 12, 2021

BUY
$15.9 - $25.22 $63,902 - $101,359
4,019 Added 3.49%
119,217 $3.01 Million
Q2 2021

Aug 16, 2021

BUY
$17.37 - $25.34 $729,540 - $1.06 Million
42,000 Added 57.38%
115,198 $2.04 Million
Q1 2021

May 17, 2021

BUY
$23.67 - $36.85 $123,131 - $191,693
5,202 Added 7.65%
73,198 $1.79 Million
Q4 2020

Feb 16, 2021

BUY
$20.32 - $39.8 $693,968 - $1.36 Million
34,152 Added 100.91%
67,996 $2.3 Million
Q3 2020

Nov 16, 2020

BUY
$19.5 - $31.26 $2,944 - $4,720
151 Added 0.45%
33,844 $846,000
Q2 2020

Aug 14, 2020

BUY
$25.68 - $38.12 $865,236 - $1.28 Million
33,693 New
33,693 $1.14 Million

Others Institutions Holding ORIC

About Oric Pharmaceuticals, Inc.


  • Ticker ORIC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,576,700
  • Market Cap $336M
  • Description
  • ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment r...
More about ORIC
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.